Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial

BACKGROUND: Treatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the multitarget tyrosine kinase inhibitor anlotinib in RM-NPC is unclear. METHODS: In this prospective, single-arm, phase 2 trial, patients with histolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yu, Su, Ning, Zou, Qihua, Cao, Yi, Xia, Yi, Tang, Linquan, Tian, Xiaopeng, Liu, Panpan, Cai, Qingqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631002/
https://www.ncbi.nlm.nih.gov/pubmed/37936166
http://dx.doi.org/10.1186/s12916-023-03140-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631002/
https://www.ncbi.nlm.nih.gov/pubmed/37936166
http://dx.doi.org/10.1186/s12916-023-03140-x

Ejemplares similares